Sputnik Light, the single-dose version of Russia's Sputnik V vaccine has got the Drug Controller General of India (DCGI) approval for Phase III clinical trials in India.
Sputnik V (Gam-Covid-Vac) is the world's first vaccine against coronavirus, registered in August 2020. Sputnik Light is its new first component based on human adenovirus serotype 26.
Sputnik V is a two-dose vaccine that targets the immune cells for quick antibody production. Sputnik Light is a single-dose vaccine that uses recombinant human adenovirus number 26 to transport requisite information into the system.
Sputnik Light is reportedly less effective against the Beta variant or coronavirus but offers good odds of protection against others, including the deadly Delta variant. It's said to be ideal for areas with acute outbreaks. This will also help in vaccinating more people as early as possible.
Sputnik Light shows 79.4 % efficacy as per the data from Russia’s mass vaccination programs while Sputnik V is 91.6% efficient against COVID-19 as per the reports published in The Lancet.
Sputnik V Vaccine is developed by Russia’s Gamaleya Research Institute of Epidemiology and Microbiology. The central government has fixed Rs. 1145 as the maximum price of Sputnik V vaccine in private hospitals. Sputnik Light single-dose vaccine can come in October for consumers. Russian Direct Investment Fund (RDIF) has tied up with six Indian drug makers to manufacture Sputnik V. Dr. Reddy’s is in a pact with the Russian Direct Investment Fund to sell the first 125 million people doses (250 million vials) of COVID-19 vaccine Sputnik V in India.